DEBORAH HORN: Open Payments
NPI 1437202355 · BELLAIRE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$125,133 in 140 payments from 9 companies in 2025. Trend: 2023 $73,753 · 2024 $135,920 · 2025 $125,133
Consulting: $65,866Speaker / faculty: $37,436Travel & lodging: $18,313Food & beverage: $3,519
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 36 | $53,259 |
| Eli Lilly and Company | 47 | $27,736 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 20 | $16,885 |
| Lilly USA, LLC | 25 | $14,097 |
| Amgen Inc. | 2 | $4,508 |
| AstraZeneca UK Limited | 4 | $3,977 |
| F. Hoffmann-La Roche AG | 1 | $2,400 |
| Novo Nordisk AS | 3 | $2,093 |
| Medtronic, Inc. | 2 | $178 |
Products named: Wegovy, ZEPBOUND, MOUNJARO, SIGNIA, PTEYE PARATHYROID DETECTION SYSTEM.
Industry payments across TX — which companies pay providers there.
